SI1849470T2 - Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze - Google Patents

Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze

Info

Publication number
SI1849470T2
SI1849470T2 SI200632192T SI200632192T SI1849470T2 SI 1849470 T2 SI1849470 T2 SI 1849470T2 SI 200632192 T SI200632192 T SI 200632192T SI 200632192 T SI200632192 T SI 200632192T SI 1849470 T2 SI1849470 T2 SI 1849470T2
Authority
SI
Slovenia
Prior art keywords
alpha
trifluorothymidine
anticancer drug
drug containing
phosphorylase inhibitor
Prior art date
Application number
SI200632192T
Other languages
English (en)
Slovenian (sl)
Other versions
SI1849470T1 (sl
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1849470(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of SI1849470T1 publication Critical patent/SI1849470T1/sl
Publication of SI1849470T2 publication Critical patent/SI1849470T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200632192T 2005-01-26 2006-01-25 Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze SI1849470T2 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
EP06712292.9A EP1849470B2 (en) 2005-01-26 2006-01-25 Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Publications (2)

Publication Number Publication Date
SI1849470T1 SI1849470T1 (sl) 2017-10-30
SI1849470T2 true SI1849470T2 (sl) 2024-05-31

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632192T SI1849470T2 (sl) 2005-01-26 2006-01-25 Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze

Country Status (20)

Country Link
EP (1) EP1849470B2 (https=)
JP (1) JP5576591B2 (https=)
KR (1) KR101468216B1 (https=)
AU (1) AU2006209547C1 (https=)
BE (1) BE2017C028I2 (https=)
CA (1) CA2594713A1 (https=)
CY (2) CY2017029I2 (https=)
DK (1) DK1849470T4 (https=)
ES (1) ES2630002T5 (https=)
FI (1) FI1849470T4 (https=)
FR (1) FR17C1028I2 (https=)
HU (2) HUE033306T2 (https=)
LT (2) LT1849470T (https=)
LU (1) LUC00036I2 (https=)
NL (1) NL300889I2 (https=)
PL (1) PL1849470T5 (https=)
PT (1) PT1849470T (https=)
SI (1) SI1849470T2 (https=)
TW (1) TWI362265B (https=)
WO (1) WO2006080327A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8536188B2 (en) * 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
JP2011520845A (ja) * 2008-05-15 2011-07-21 カソリック ユニヴェルシテイト ルーヴェン，ケー．ユー． ルーヴェン アール アンド ディー 抗癌剤の組合せによる治療
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
US9371380B2 (en) 2011-08-16 2016-06-21 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
JP6002835B2 (ja) * 2013-03-27 2016-10-05 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
KR101847252B1 (ko) * 2013-03-27 2018-04-09 다이호야쿠힌고교 가부시키가이샤 이리노테칸염산염 수화물을 함유하는 항종양제
AU2014266278B2 (en) * 2013-05-17 2017-07-13 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of TK1 protein has increased
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
HRP20230523T1 (hr) 2013-09-06 2023-08-04 Taiho Pharmaceutical Co., Ltd. Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
WO2017119484A1 (ja) * 2016-01-08 2017-07-13 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
MA43977A (fr) 2016-02-05 2018-12-12 Taiho Pharmaceutical Co Ltd Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2026019875A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100424934B1 (ko) * 1995-03-29 2004-07-27 다이호야쿠힌고교 가부시키가이샤 우라실유도체및이를함유하는항종양효과증강제및항종양제
AU699728B2 (en) * 1996-09-24 1998-12-10 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Also Published As

Publication number Publication date
RU2394581C2 (ru) 2010-07-20
LUC00036I2 (https=) 2017-12-01
NL300889I1 (nl) 2017-08-14
ES2630002T3 (es) 2017-08-17
ES2630002T5 (es) 2024-09-19
PL1849470T5 (pl) 2024-06-10
JP5576591B2 (ja) 2014-08-20
SI1849470T1 (sl) 2017-10-30
CY2017029I1 (el) 2018-02-14
FR17C1028I1 (https=) 2017-09-29
LUC00036I1 (https=) 2017-10-02
DK1849470T4 (en) 2024-04-02
CY1119393T1 (el) 2018-02-14
PL1849470T3 (pl) 2017-11-30
AU2006209547B2 (en) 2011-05-26
DK1849470T3 (en) 2017-08-14
KR20070104559A (ko) 2007-10-26
NL300889I2 (nl) 2018-01-16
FI1849470T4 (fi) 2024-03-22
TW200637562A (en) 2006-11-01
LTPA2017024I1 (lt) 2017-08-10
CY2017029I2 (el) 2018-02-14
HUE033306T2 (hu) 2017-11-28
EP1849470B1 (en) 2017-06-21
LTC1849470I2 (lt) 2019-10-25
FR17C1028I2 (fr) 2018-11-02
EP1849470B2 (en) 2024-03-20
HUS1700032I1 (hu) 2017-09-28
PT1849470T (pt) 2017-09-22
AU2006209547C1 (en) 2022-04-07
WO2006080327A1 (ja) 2006-08-03
BE2017C028I2 (https=) 2025-09-10
TWI362265B (en) 2012-04-21
JPWO2006080327A1 (ja) 2008-06-19
EP1849470A4 (en) 2010-12-08
EP1849470A1 (en) 2007-10-31
CA2594713A1 (en) 2006-08-03
AU2006209547A1 (en) 2006-08-03
KR101468216B1 (ko) 2014-12-03
LT1849470T (lt) 2017-07-25
RU2007132181A (ru) 2009-03-10

Similar Documents

Publication Publication Date Title
LT1849470T (lt) Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius
SI1913001T1 (sl) (r)-n-metilnaltrekson, postopki za njega sintezo in njega farmacevtsko uporabo
SI1928882T1 (sl) (s)-n-metilnaltrekson, postopek za njega sintezo in njega farmacevtska uporaba
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
ZA200709856B (en) Fluorene derivatives,compositions containing said derivatives and the use thereof
IL194751A0 (en) Drugs and uses
SI2057153T1 (sl) (3-ril-piperazin-1-il) derivati 6,7-dialkoksikuinazolin, 6,7-dialkoksiftalazin in 6,7-dialkoksiizokuinolin
PL2034015T3 (pl) Immunostymulujący oligonukleotyd i jego zastosowanie farmaceutyczne
IL198236A0 (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
AP2008004533A0 (en) Pharmaceutical combination
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
GB0516069D0 (en) Pharmaceutical and use thereof
ZA200804666B (en) Pharmaceutical combination
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
PL1791872T3 (pl) Biotynylowane heksadekasacharydy, kompozycje farmaceutyczne i ich zastosowanie
EP1915988A4 (en) COMPRESSOR COMPRISING MULTIPLE SEGMENTS CONTAINING MEDICAMENTS
IL177759A0 (en) Cospeptin, cosmedin and their uses
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
IL191618A0 (en) N-hydroxyamide derivatives, their preparation and use
TWI372053B (en) Combination drug
AP2008004389A0 (en) Pharmaceutical combinations containing lamivudine,stavudine,stavudine and navirapine
HK1118825A (en) Substituted oxindol-derivatives, medicaments containing said derivatives and use thereof
AU2005903086A0 (en) Medicaments and uses thereof
GB0500826D0 (en) Pharmaceutical use